Status:
COMPLETED
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT. The s...
Detailed Description
Subjects will be provided with a saliva collection kit which can be used at home. Subjects will return the collection kit in a paid, pre-addressed mailer to the laboratory at Biomodels. The laboratory...
Eligibility Criteria
Inclusion
- Have given informed consent to submit a sample of saliva for DNA isolation and SNP analysis
- Have undergone autologous HSCT for treatment of Hodgkin's or non-Hodgkin's lymphoma or multiple myeloma at the Dana-Farber Cancer Institute from 1/1/2006 through 6/30/2010
- Have medical records identifying whether the participants did or did not develop severe mucositis
Exclusion
- Received Palifermin (Kepivance) prior to their conditioning regimen
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT01402687
Start Date
October 1 2010
End Date
June 1 2013
Last Update
July 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02214